13 Patent Results (11 families)
Make Note

Insulin Glargine/lixisenatide Fixed Ratio Formulation

  • Published: Apr 24, 2018
  • Filed: Dec 10, 2015
  • Earliest Priority: Dec 12 2014
  • Family: 22
  • Cited Works: 939
  • Cited by: 0
  • Cites: 514
  • Sequences: 2
  • Additional Info: Cited Works Full text Published Sequence
  • Owner: Sanofi-aventis Deutschland Gmbh, Saudi Arabian Oil Company
  • Applicant: Sanofi Aventis Deutschland
Granted Patent
US 9950039 B2
033-689-058-528-511

Pharmaceutical Composition For Use In The Treatment Of A Neurodegenerative Disease

Granted Patent
US 9987332 B2
172-049-723-445-228

Use Of Ave0010 For The Treatment Of Diabetes Mellitus Type 2

  • Published: May 29, 2018
  • Filed: Aug 15, 2016
  • Earliest Priority: Aug 30 2010
  • Family: 32
  • Cited Works: 940
  • Cited by: 0
  • Cites: 520
  • Sequences: 2
  • Additional Info: Cited Works Full text Published Sequence
  • Owner: Sanofi-aventis Deutschland Gmbh
  • Applicant: Sanofi Aventis Deutschland
Granted Patent
US 9981013 B2
111-178-210-333-675

Pharmaceutical Combination For Improving Glycemic Control As Add-on Therapy To Basal Insulin

  • Published: Nov 21, 2017
  • Filed: May 9, 2012
  • Earliest Priority: May 13 2011
  • Family: 29
  • Cited Works: 941
  • Cited by: 2
  • Cites: 510
  • Sequences: 2
  • Additional Info: Cited Works Full text Published Sequence
  • Owner: Sanofi-aventis Deutschland Gmbh
  • Applicant: Niemoeller Elisabeth, Silvestre Louise, Boka Gabor, Miossec Patrick, Sanofi Aventis Deutschland
Granted Patent
US 9821032 B2
138-229-978-160-983

Treatment Of Type 2 Diabetes Mellitus Patients

  • Published: Dec 25, 2018
  • Filed: Mar 17, 2016
  • Earliest Priority: Mar 18 2015
  • Family: 21
  • Cited Works: 1036
  • Cited by: 0
  • Cites: 522
  • Sequences: 2
  • Additional Info: Cited Works Full text Published Sequence
  • Owner: Sanofi-aventis Deutschland Gmbh
  • Applicant: Sanofi Aventis Deutschland
Granted Patent
US 10159713 B2
070-100-365-998-051

Pharmaceutical Composition Comprising A Glp-1 Agonist And Methionine

  • Published: Jul 18, 2017
  • Filed: Nov 11, 2010
  • Earliest Priority: Nov 13 2009
  • Family: 54
  • Cited Works: 849
  • Cited by: 0
  • Cites: 529
  • Additional Info: Cited Works Full text Published
  • Owner: Sanofi-aventis Deutschland Gmbh
  • Applicant: Brunner-schwarz Anette, Mueller Werner, Siefke-henzler Verena, Sanofi Aventis Deutschland
Granted Patent
US 9707176 B2
002-447-756-954-909

Pharmaceutical Composition Comprising A Glp-1-agonist And Methionine

  • Published: Jul 24, 2018
  • Filed: May 15, 2017
  • Earliest Priority: Nov 13 2009
  • Family: 54
  • Cited Works: 971
  • Cited by: 0
  • Cites: 520
  • Sequences: 4
  • Additional Info: Cited Works Full text Published Sequence
  • Owner: Sanofi-aventis Deutschland Gmbh
  • Applicant: Sanofi Aventis Deutschland
Granted Patent
US 10028910 B2
099-183-108-461-543

Pharmaceutical Composition Comprising A Glp-1 Agonist, An Insulin And Methionine

  • Published: Jul 24, 2018
  • Filed: Nov 11, 2010
  • Earliest Priority: Nov 13 2009
  • Family: 65
  • Cited Works: 967
  • Cited by: 0
  • Cites: 504
  • Additional Info: Cited Works Full text Published
  • Owner: Sanofi-aventis Deutschland Gmbh
  • Applicant: Hagendorf Annika, Hauck Gerrit, Mueller Werner, Schoettle Isabell, Siefke Henzler Verena, Tertsch Katrin, Sanofi Aventis Deutschland
Granted Patent
US 10029011 B2
196-519-363-466-387

High-purity Quinoline Derivative And Method For Manufacturing Same

  • Published: Apr 16, 2019
  • Filed: Aug 26, 2015
  • Earliest Priority: Aug 28 2014
  • Family: 19
  • Cited Works: 2017
  • Cited by: 0
  • Cites: 497
  • Additional Info: Cited Works Full text
  • Owner: Eisai R&d Management Co. Ltd
  • Applicant: Eisai R&d Man Co Ltd
Granted Patent
US 10259791 B2
158-895-687-542-471

High-purity Quinoline Derivative And Method For Manufacturing Same

  • Published: Sep 10, 2019
  • Filed: Dec 21, 2018
  • Earliest Priority: Aug 28 2014
  • Family: 19
  • Cited Works: 2067
  • Cited by: 0
  • Cites: 515
  • Additional Info: Cited Works Full text
  • Owner: Eisai R&d Management Co. Ltd
  • Applicant: Eisai R&d Man Co Ltd
Granted Patent
US 10407393 B2
166-735-160-132-22X
{{::'analysis.preview.CITED_WORKS_ANALYSIS.title' | message}} {{::'analysis.preview.view.full' | message}}

Add New Note

Sorry, you can't add a note to multiple items. You can add a note to your search as a saved query. Did you want to save this search and add a note to it?

Cancel Save
Search ORCID

Sign in to the Lens

Forgot Password? Register New Account
Feedback